tbuckley/cabot-search huggingface dataset:
Glucagon-like peptide-1 receptor agonists and risk of breast cancer
Authors: Shari D Bolen, Nisa M Maruthur
Journal: BMJ (2016)

Concern remains, and should feature in discussions with patients

Although many providers and some patients know about the potential risks of pancreatic or thyroid cancer with use of glucagon-like peptide-1 (GLP-1) receptor agonists,1 2 3 risk of breast cancer has also recently arisen as a potential risk with these drugs. The US Federal Drug Administration (FDA) and European Medicines Agency separately conducted pooled analyses of four weight management trials that investigated the use of 3.0 mg liraglutide (a type of GLP-1 receptor agonist).4 5 In these pooled analyses, 12 (0.29%) breast cancer events were reported in the liraglutide arms versus two (0.08%) events in the placebo arms.

Given the rare occurrence of these events, it was unclear whether this difference was due to chance alone or a true increase in breast cancer risk. The LEADER trial (liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results) compared liraglutide at a lower dose of …
A phase I study of q3W R1507, a human monoclonal antibody IGF-1R antagonist in patients with advanced cancer
Authors: J. Rodon, A. Patnaik, M. Stein, A. Tolcher, C. Ng, C. Dias, M. Kurman, G. Greig, R. Kurzrock, E. Rubin
Journal: Journal of Clinical Oncology (2007)

3590 Background: Insulin-like growth factor receptor (IGF-1R) is a tyrosine kinase cell surface receptor overexpressed in cancer cells which mediates the mitogenic and anti-apoptotic actions of IGF, playing a key role in malignant transformation. The safety and pharmacokinetics of 3-weekly administration of R1507, a human monoclonal antibody selective for IGF-1R, were explored in this phase I dose escalation study in patients with advanced solid tumors or lymphomas. Materials and Methods: Multiple ascending doses of R1507 were administered as a 1 hour infusion every 3 weeks until the development of dose-limiting toxicity (DLT) or progressive disease. Inclusion criteria: ECOG PS 0–1, adequate hematologic, hepatic, and renal function, CD4 count &gt;200/μl. Exclusion criteria: infection, immunosuppressive agents, diabetes mellitus, uncontrolled systemic disease, NYHA III/IV CHF. DLT defined as ≥ grade 2 hypersensitivity reaction; ≥ grade 3 non-hematologic toxicity; ≥ grade 2 cardiac toxicity; ≥ grade 3 hematologic toxicity = 7 days, or dose delay &gt; 1 week due to toxicity. Blood samples were collected following 1 st dose for non compartmental PK analysis and for future analysis of IGF-1R levels. Results: 21 patients (pts) (M:F 14:7) were enrolled in 1 of 4 dose levels (dose range 1–16 mg/kg). Mean pt age 57 yrs (range: 30–81), mean prior treatments 4.6 (range: 1–9). Mean treatment cycles 2.6 (range: 1- 6). Six pts remain on study. Adverse events (AE) included infection (6 pts), fatigue (4); rash, fever, arthralgia, cough, diarrhoea, abdominal and back pain (3 each). No DLT or serious AEs attributed to study drug were reported. Activity: 10 pts showed stable disease (median 33 days). PK: Clearance (CL) decreased from 812 mL/Day (Coefficient of Variation [CV] =19.9%) in the 1 mg/kg group to 418 mL/Day (CV=46.7%) in the 16 mg/kg group; Volume of distribution was in the range of 4.4 - 5.4 L (CV=10.9–34.8%). T 1/2 increased from 4 to 9 days. Conclusions: Treatment with R1507 is tolerable at the dose of 16mg/kg q3W. Treatment-related toxicities are mild and clinically manageable. Decrease in CL across doses levels suggests a saturable elimination pathway. T1/2 value of ∼8 days supports a weekly dosing for future trials. [Table: see text]
Transplantation From 8/8-Matched or 7/8-Matched Unrelated Donors Compared with HLA-Matched Siblings in Acute Myeloid Leukemia in First Complete Remission
Authors: Byung-Sik Cho, Jae-Ho Yoon, Seung-Hwan Shin, Seung-Ah Yahng, Sung-Eun Lee, Ki-Seong Eom, Yoo-Jin Kim, Seok Lee, Chang-Ki Min, Seok-Goo Cho, Dong-Wook Kim, Jong-Wook Lee, Woo-Sung Min, Chong-Won Park, Hee-je Kim
Journal: Blood (2012)
Topical use of topical fibrin sealant can reduce the need for transfusion, total blood loss and the volume of drainage in total knee and hip arthroplasty: A systematic review and meta-analysis of 1489 patients
Authors: Jie Li, Hong-biao Li, Xi-cheng Zhai, None Qin-lei, Xin-qiang Jiang, Zhen-hua Zhang
Journal: International Journal of Surgery (2016)
Response to Interleukin (IL)-17 Inhibition in an Adolescent With Severe Manifestations of IL-36 Receptor Antagonist Deficiency (DITRA)
Authors: Kelly M. Cordoro, Derya Ucmak, Maria Hitraya-Low, Michael D. Rosenblum, Wilson Liao
Journal: JAMA Dermatology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Graft-Vs-Graft Immune Interaction Is the Likely Mechanism of Absolute Unit Dominance in Double Unit Cord Blood (DCB) Transplantation Using Patient DCB Grafts: An in Vivo but Not in Vitro Phenomenon
Authors: Lamis K Eldjerou, Sonali Chaudhury, Mai He, Maria E Arcila, Paulo A Salazar, Richard J O’Reilly, Juliet N Barker, Malcolm A.S. Moore
Journal: Blood (2008)
Metformin improves defective hematopoiesis and delays tumor formation in Fanconi anemia mice
Authors: Qing-Shuo Zhang, Weiliang Tang, Matthew Deater, Ngoc Phan, Andrea N. Marcogliese, Hui Li, Muhsen Al-Dhalimy, Angela Major, Susan Olson, Raymond J. Monnat, Markus Grompe
Journal: Blood (2016)
Carbon Monoxide Poisoning: Pathogenesis, Management, and Future Directions of Therapy
Authors: Jason J. Rose, Ling Wang, Qinzi Xu, Charles F. McTiernan, Sruti Shiva, Jesus Tejero, Mark T. Gladwin
Journal: American Journal of Respiratory and Critical Care Medicine (2016)

Carbon monoxide (CO) poisoning affects 50,000 people a year in the United States. The clinical presentation runs a spectrum, ranging from headache and dizziness to coma and death, with a mortality rate ranging from 1 to 3%. A significant number of patients who survive CO poisoning suffer from long-term neurological and affective sequelae. The neurologic deficits do not necessarily correlate with blood CO levels but likely result from the pleiotropic effects of CO on cellular mitochondrial respiration, cellular energy utilization, inflammation, and free radical generation, especially in the brain and heart. Long-term neurocognitive deficits occur in 15-40% of patients, whereas approximately one-third of moderate to severely poisoned patients exhibit cardiac dysfunction, including arrhythmia, left ventricular systolic dysfunction, and myocardial infarction. Imaging studies reveal cerebral white matter hyperintensities, with delayed posthypoxic leukoencephalopathy or diffuse brain atrophy. Management of these patients requires the identification of accompanying drug ingestions, especially in the setting of intentional poisoning, fire-related toxic gas exposures, and inhalational injuries. Conventional therapy is limited to normobaric and hyperbaric oxygen, with no available antidotal therapy. Although hyperbaric oxygen significantly reduces the permanent neurological and affective effects of CO poisoning, a portion of survivors still have substantial morbidity. There has been some early success in therapies targeting the downstream inflammatory and oxidative effects of CO poisoning. New methods to directly target the toxic effect of CO, such as CO scavenging agents, are currently under development.
Effect of Matrine on Alleviating Retinoic Acid Resisted Acute Promyelocytic Leukemia
Authors: Jie Sun, Di Jiong Wu, He Huang, Yuhong Zhou, Jun Zhu, Wei Zhao, Weijun Zhong, Zhen Wang, Huan Qian, Rui Li, Shan Fu
Journal: Blood (2010)
Lymphopenia Prior High-Dose Chemotherapy Is a Major Prognostic Factor for Severe Infectious Complication after Autologous Blood Stem Cell Transplantation for Lymphoma’s Patients.
Authors: Hervé Ghesquières, Roch Houot, Céline Ferlay, Catherine Sebban, Thérèse Gargi, Irène Philip, Pierre Biron, Isabelle Ray-Coquard, Jean-Yves Blay
Journal: Blood (2006)
CD8+/TCR− Graft Facilitating Cells Enhance HSC Engraftment and Survival Via TNF-α Mediated Prevention of Apoptosis.
Authors: Suzanne T. Ildstad, Francine Rezzoug, Yiming Huang, Marcin Wysoczynski, Carrie L. Schanie, Mariusz Z. Ratajczak, Isabelle J. Fugier-Vivier
Journal: Blood (2005)
Remission Induction with Cladribine, Cytarabine and Idarubicin (CAI) in Elderly Patients with Relapsed AML - A Pilot Study.
Authors: Marie von Lilienfeld-Toal, Corinna Hahn-Ast, Katjana Orlopp, Schmidt-Wolf G.H. Ingo, Glasmacher Axel
Journal: Blood (2006)
PTU-217 Hypervirulent clostridium difficile has a unique odour profile: Abstract PTU-217 Table 1
Authors: S Reade, H Simpson, RBM Aggio, CSJ Probert
Journal: Gut (2015)

<h3>Introduction</h3> <i>C. difficile</i>is a spore-forming bacterium that causes infectious diarrhoea, having a characteristic odour. Symptoms range from a mild disturbance to severe illness with ulceration and bleeding from the colon and perforation of the intestine. Patients treated with broad spectrum antibiotics are at the greatest risk of contracting <i>C. difficile</i>infection. Problematic ribotypes have been defined. PCR-based tests depend on a prior knowledge of the gene sequences of strains being detected and thus new or different strains may be missed. A test that is dependent on metabolic volatile organic compounds (VOCs) would be free from such constraints. <h3>Method</h3> Briefly, 4 <i>C. difficile</i>strains, separated by their genotype and toxin expression (toxins: A, B or binary), were cultured on fastidious anaerobe (FA) agar and later in FA broth cultures. Headspace gases were collected using a CAR/PDMS/DVB SPME fibre before GC-MS analysis. Chromatograms were analysed and data was processed in-house using AMDIS and Metab. A one-way ANOVA followed by Tukey with Bonferroni multiple comparison correction were performed (<i>p &lt; </i>0.001). <h3>Results</h3> <h3>Conclusion</h3> Combinations of VOCs were found to be characteristic to each of the four ribotypes. These results point to potential indicators of different metabolic pathways in virulent (108536/027) and less-virulent strains. The pipeline of analysis used in this study has enabled the chemical identification of VOCs, providing an insight into the underlying metabolic pathways that are active during bacterial growth. Rapid detection of VOCs emitted from the HS of <i>C. difficile</i>may have the utility as a non-invasive diagnostic test. <h3>Disclosure of interest</h3> None Declared.
Selective Inhibitors of Arginine Methyl Transferase 5 (PRMT5) As a Novel Treatment for β-Thalassemia and Sickle Cell Disease.
Authors: Ian Street, Brendon Monahan, Hendrik Falk, Elizabeth Allan, Ylva Bergman, Paul Stupple, Ian Holmes, Alison Gregg, Susan Charman, Kurt Lackovic, Tom Peat, Scott Walker, Kym Lowes, Wilco Kersten, Jo Alcindor, Matthew Chung, Michael Parker, Richard Foitzik, Michelle Camerino, Marcia Nikac, Julian Grusovin, Pat Pilling, Stefan Sonderegger, Yuen Tan, Quan Zhao, David J. Curtis, Stephen M Jane
Journal: Blood (2012)
Patient perceptions of the side effects of anticancer therapy.
Authors: F. Puglisi, L. Deroma, I. Rizzetto, P. Driol, R. Sottile, G. Pascoletti, S. Moroso, G. Fasola, S. Russo
Journal: Journal of Clinical Oncology (2010)

e19623 Background: Analysis of relative importance of side effects of anticancer therapy is extremely useful in the process of clinical decision making. Previous studies have surveyed what patients consider to be side effects of chemotherapy and their perceptions of the impact of these complaints. We conducted a survey to identify and rank the side effects of anticancer agents perceived by patients in 2009. Methods: Two hundred and one consecutive patients (81 men and 120 women; median age: 62 years) receiving outpatient chemotherapy at the Department of Oncology of Udine, Italy, were included. The interview was conducted using a questionnaire and 2 sets of cards naming physical (45 cards) and non-physical (28 cards) effects, respectively. Patients were asked to select from cards all side effects experienced and the 5 most troublesome of each group. The resulting 10 cards were reshuffled, and patients were asked to rank the side effects in order of severity, irrespective of their original group. Data were analyzed according to different factors such as marital status, occupation, diagnosis and treatment. Results: Patients ranked the non-physical side effect “affects my family or partner” 1st. “Loss of hair” was ranked 2nd and “constantly tired” 3rd. The complaints “pins and needles in the limb” and “constipation” were ranked as 4th and 5th, respectively. Of note, some deviations from the overall rank order were observed in certain subgroups. For example, “loss of hair” was ranked 6th in men and 2nd in women, while “nausea” was ranked 5th in men and 8th in women. Interestingly, “affects my family or partner” was ranked 1st by patients younger than 70 years and 5th by older patients. The present study showed some differences with a previous survey conducted in 1983. In that study, most relevant complaint was “vomiting”, whereas “nausea” and “loss of hair” were ranked 2nd and 3rd, respectively. “Affects family or partner” was ranked 10th. In contrast, no substantial differences were observed between our study and a French study published in 2002. Conclusions: Anticancer treatments and supportive care continue to evolve. Updated surveys on what patients consider side effect of anticancer therapy may identify factors that may influence the process of clinical decision making. No significant financial relationships to disclose.
Ibrutinib in Early Stage CLL: Preliminary Safety Results of a Placebo-Controlled Phase III Study
Authors: Petra Langerbeins, Jasmin Bahlo, Christina Rhein, Paula Cramer, Anna-Maria Fink, Natali Pflug, Julia von Tresckow, Stephan Stilgenbauer, Karl-Anton Kreuzer, Michael J. Eckart, Ursula Vehling-Kaiser, Rudolf Schlag, Christina Balser, Lothar Müller, Clemens-Martin Wendtner, Kirsten Fischer, Barbara Eichhorst, Michael Hallek
Journal: Blood (2015)
MEK Inhibitor AZD6244 Induces Cell Growth Arrest and Synergizes Nutlin-3a-Mediated Cell Death by Upregulating p53 and PUMA Levels in Acute Myelogenous Leukemia.
Authors: Weiguo Zhang, Marina Konopleva, Wendy D. Schober, Teresa McQueen, Michael Andreeff
Journal: Blood (2007)
Treatment of pseudomyxoma peritonei by intraoperative and intraperitoneal chemotherapy
Authors: M. Friedrich, W. Poleska, J. Baltzer, D. Salehin
Journal: Journal of Clinical Oncology (2009)

e16540 Background: Pseudomyxoma peritonei occurs mostly in conjunction with the type of intestinal mucinous borderline tumour and is characterized by building up a lot of mucus pour of cells. The most common tumor is the pseudomyxoma peritoneii with mucinous borderline tumours of the ovaries or with mucinous tumours of the appendix, normally without showing a rupture of the ovarian tumour pre- or intraoperatively. The diagnosis of pseudomyxoma peritonei is mainly difficult and guidelines for the treatment are unknown. Methods: In the period from 1991 to 2008, 52 patients with pseudomyxoma peritonei were treated by tumour debulking and intraoperative and intraperitoneal chemotherapy with Mitoxantron (40 mg in 300 ml of NaCl over 72 hours). During the tumour debulking a CUSA system was used. Results: The median follow-up was 8.2 years. There were the following histologies: mucinous cystadenoma of the ovary n = 29, mucinous cystadenoma of the appendix n = 10, mucinous cystadenocarcinoma n = 13. Reccurrences were seen in 4 patients. These patients were treated for reccurrences by the same way as mention above. All these patients were now without any recurrences. The other 48 patients are still alive with recurrences. Conclusions: The instillation of mitoxantron intraperitoneally and intraoperatively is an effective and safe therapy without any side effects after maximal tumour debulking of pseudomyxoma peritoneii. No significant financial relationships to disclose.
Isolated Metachronous Splenic Metastasis From Colon Cancer Found by 18F-FDG PET/CT
Authors: Laura Gilardi, Manuela Vadrucci
Journal: Clinical Nuclear Medicine (2016)

Isolated splenic metastases from solid malignancies are very rare. We report the case of a 58-year-old woman with isolated metachronous splenic metastasis from colon cancer detected 18 months after colectomy. 18F-FDG PET/CT allowed its recognition and guided the therapeutic approach toward surgery.
Discordence of HER-2/neu overexpression and estrogen receptor between the primary breast cancer and axillary lymph node with metastasis
Authors: R. K. Shahid, I. Ahmad, S. Yadav, A. Sami, K. Haider, H. Rees, S. Ahmed
Journal: Journal of Clinical Oncology (2006)

20106 Background: Adjuvant hormonal therapy and trastuzumab are known to be associated with a significant reduction in cancer-related mortality in a subset of women with breast cancer. The treatment decision is usually based on immunohistochemistry (IHC) staining of the primary tumor. We reported here a case of discordance of HER-2/neu overexpression and estrogen receptor status between the primary breast cancer and axillary lymph node with metastasis. Methods: IHC and fluorescence in situ hybridization (FISH) analysis was perfromed for the assessment of HER-2/neu. E-cadherin staining was done on the primary tumor and lymph node with metastasis. Results: A 52 year old woman presented with right breast lump. The imaging studies showed a 5 × 5 cm speculated mass. No other abnormalities were noted. An excision biopsy revealed 3 cm moderately differentiated invasive lobular carcinoma. Subsequently a wider excision and axillary lymph node dissection was done. 2/20 lymph nodes were involved by the cancer. IHC was done in the primary tumor and the lymph node with metastasis. IHC of the primary tumor revealed less than 1% nuclei positive for estrogen receptor (ER), 0% nuclei positive for progesterone receptor (PR), and no HER-2/neu overexpression. IHC of the lymph nodes with metastasis revealed 80% nuclei positive for ER, less than 1% nuclei positive for PR, and equivocal HER-2/neu overexpression. FISH analysis for HER-2/neu gene was done on the primary tumor which revealed no amplification in the tumor nuclei (Her2/CEP17 ratio was 3.6/2.7 = 1.3) whereas FISH analysis on the lymph node section revealed amplification in tumor nuclei (Her2/CEP 17 ratio of 7.3/1.9 = 3.9). E-cadherin staining of the primary breast tumor as well as the lymph node with metastasis revealed no membrane staining of the malignant cells in either section. Conclusions: The unusual occurrence of a divergent IHC profile and FISH analysis results between the primary carcinoma and metastatic carcinoma may be due to a subselection of a malignant clone which were not represented in the section of primary tumor chosen for IHC. Future studies are required to determine the utility of IHC staining of metastatic cells involving the lymph nodes if primary tumor is negative for HER-2/neu &amp; ER. No significant financial relationships to disclose.
G-CSF-Stimulation of Human Marrow Stromal Cells Induces In Vitro Migration of Hematopoietic Progenitor Cells Involving MMP-2 and MMP-9 but Not MMP-1.
Authors: Adriana López, Valérie Chabot, Pascal Vaudin, Nathalie Clément, Olivier Hérault, Pierre Charbord, Jorge Domenech
Journal: Blood (2004)
PGAM5: a new player in immune-mediated liver injury
Authors: Anup Ramachandran, Hartmut Jaeschke
Journal: Gut (2016)

Mechanisms of cell death are critical in any pathophysiology and hence have been extensively investigated in a number of different organ systems. Initially, the term ‘programmed cell death’ was exclusively applied to apoptosis, where molecular mediators and signalling pathways involved in the process were relatively well characterised. The other form of cell death, namely necrosis, was considered to be an uncontrolled process, where catastrophic events within the cell resulted in a rupture of the plasma membrane with release of cell contents. However, this paradigm has been rapidly evolving as new pathways and mediators, which control necrotic cell death, are discovered. It is now clear that whenever cells die by necrosis, they do so in an ordered systematic manner, which, not surprisingly, shares some components with the apoptotic pathway. This is especially relevant in the liver, where apoptosis was considered to be the main form of cell death in a large number of contexts. These concepts are now changing based on the identification of specific mediators involved in programmed necrosis in response to a number of insults in the liver. The new study from He et al 1 in this issue now identifies mitochondrial phosphoglycerate mutase/protein phosphatase 5 (PGAM5) as another key mediator in physiologically relevant cell death in the liver, …
The Impact of Trauma Care Systems in Low- and Middle-Income Countries
Authors: Teri A. Reynolds, Barclay Stewart, Isobel Drewett, Stacy Salerno, Hendry R. Sawe, Tamitza Toroyan, Charles Mock
Journal: Annual Review of Public Health (2015)

Injury is a leading cause of death globally, and organized trauma care systems have been shown to save lives. However, even though most injuries occur in low- and middle-income countries (LMICs), most trauma care research comes from high-income countries where systems have been implemented with few resource constraints. Little context-relevant guidance exists to help policy makers set priorities in LMICs, where resources are limited and where trauma care may be implemented in distinct ways. We have aimed to review the evidence on the impact of trauma care systems in LMICs through a systematic search of 11 databases. Reports were categorized by intervention and outcome type and summarized. Of 4,284 records retrieved, 71 reports from 32 countries met inclusion criteria. Training, prehospital systems, and overall system organization were the most commonly reported interventions. Quality-improvement, costing, rehabilitation, and legislation and governance were relatively neglected areas. Included reports may inform trauma care system planning in LMICs, and noted gaps may guide research and funding agendas.
Infection-related complications during treatment for childhood acute lymphoblastic leukemia
Authors: H. Inaba, D. Pei, J. Wolf, S.C. Howard, R.T. Hayden, M. Go, O. Varechtchouk, T. Hahn, J. Buaboonnam, M.L. Metzger, J.E. Rubnitz, R.C. Ribeiro, J.T. Sandlund, S. Jeha, C. Cheng, W.E. Evans, M.V. Relling, C.-H. Pui
Journal: Annals of Oncology (2016)